Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

125

Address:

Allakos Inc. 975 Island Drive Suite 201 Redwood City CA 94065 United States

Website:

http://www.allakos.com

Phone:

650-597-5002

Leave a comment

Your email address will not be published. Required fields are marked *